Keyword: Themis Bioscience
Themis secured £3 million from Innovate UK for its Chikungunya vaccine project.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
Themis is the most recent company to usher a Zika vaccine to the clinic.
The NIH's Zika vaccine will move into phase 2 testing, officials said Friday. Despite the president's threats of spending cuts, this project is fully funded.
A Zika vaccine safe enough for women of childbearing age may still not be available before 2020, the World Health Organization estimated.
Add PaxVax to the list of companies vying to put the first Chikungunya vaccine on the market.
With €5 million in government funding, Themis and European collaborators have teamed up to create the newest Zika vaccine partnership.
Themis closed a second round of financing worth €10 million, which will be used for its Chikungunya vaccine and to further a Zika-fighting candidate.
After tying the knot with Sanofi on testing a Zika vaccine candidate, the Walter Reed Army Institute of Research has enlisted Engility for a $10 million project testing vaccines intended to fight the mosquito-borne Chikungunya virus.
This week, Austrian biotech Themis Bioscience said it’s starting a Phase II for its Chikungunya virus vaccine, what it calls “the most advanced” candidate of its kind.